Japan Molecular Imaging Market Report by Modality, Application, End Use, Cities and Company Analysis, 2026-2034

Japan Molecular Imaging Market: Future Outlook, Growth Trends & Forecast (2026–2034)

Japan Molecular Imaging Market is expected to reach US$ 545.08 Million by 2034 from US$ 381.64 Million in 2025, with a CAGR of 4.04% from 2026 to 2034. Japan’s molecular imaging market is advancing through precision medicine, cancer screening, neurological diagnostics, and theranostics. Increasing use of PET, SPECT, advanced radiopharmaceuticals, and AI-enabled image analysis is helping clinicians visualize biological processes more precisely and support individualized treatment decisions.

Japan Molecular Imaging Industry Landscape

Molecular imaging is an advanced diagnostic approach that visualizes biological and physiological processes inside the body at the cellular or molecular level. Unlike conventional imaging, which primarily shows anatomy, molecular imaging can reveal metabolic activity, receptor expression, disease-related changes, and treatment responses. Major techniques include positron emission tomography (PET), single-photon emission computed tomography (SPECT), PET/CT, PET/MRI, and specialized radiopharmaceutical imaging. The technology supports earlier disease identification, treatment planning, therapy monitoring, and personalized medicine. In Japan, molecular imaging is particularly relevant to oncology, neurology, cardiology, and theranostics, where targeted tracers and quantitative imaging can provide clinicians with more detailed information for clinical decision-making.

Japan’s molecular imaging market is benefiting from the healthcare system’s increasing emphasis on precise diagnosis and individualized treatment. PET and SPECT allow clinicians to assess functional and metabolic changes that may not be apparent through anatomical imaging alone. This capability is particularly valuable for cancer staging, recurrence assessment, neurological disorders, and treatment monitoring. The growing integration of molecular imaging with artificial intelligence, quantitative analysis, hybrid imaging, and targeted radiopharmaceuticals is further improving clinical workflows. Japan’s research ecosystem also supports collaboration between hospitals, universities, pharmaceutical companies, and medical-device manufacturers, encouraging development of new tracers and imaging technologies. Together, these advances are strengthening the role of molecular imaging across specialized clinical pathways.

Recent Breakthroughs Shaping the Japan Molecular Imaging Industry

• In March 2025, GE HealthCare Technologies Inc. completed the acquisition of Sumitomo Chemical’s remaining 50% stake in Nihon Medi-Physics Co., Ltd. (NMP), making NMP a wholly owned subsidiary. The strategic transaction strengthened GE HealthCare’s position in Japan’s molecular imaging landscape while expanding its access to a broad portfolio of PET and SPECT radiopharmaceuticals spanning neurological, cardiovascular, and oncology applications.
• In September 2025, Lantheus Holdings, Inc. and GE HealthCare entered into an exclusive licensing agreement for PYLARIFY in Japan. Under the agreement, GE HealthCare will oversee the development, manufacturing, and commercialization of the prostate cancer PET imaging agent in Japan. The agreement represents an important advancement for PSMA-targeted molecular imaging, supporting improved prostate cancer diagnosis, disease assessment, and treatment monitoring.

Major Growth Drivers Shaping the Future of Japan Molecular Imaging Sector

1. Next-Generation PET and SPECT Technology Expands Diagnostic Capabilities

Technological innovation is transforming Japan’s molecular imaging environment by improving image quality, workflow efficiency, patient comfort, and lesion visualization. Modern digital PET/CT systems increasingly incorporate high-performance detectors, advanced time-of-flight technology, AI-assisted reconstruction, automated positioning, and compact equipment designs. These improvements can support faster examinations while helping clinicians obtain clearer information from complex cases. SPECT is also benefiting from semiconductor detectors, quantitative reconstruction, and software-assisted interpretation. The Single Photon Emission Computed Tomography market is therefore being strengthened by technological modernization, particularly where hospitals seek improved functional imaging for cardiovascular, neurological, and oncological applications.

In August 2026, United Imaging Healthcare’s uMI Panvivo received a major Japanese market milestone when its first domestic system began clinical operation at Saitama Central Clinic. The digital PET/CT combines high-resolution imaging, fast time-of-flight performance, AI-supported workflow, and a compact air-cooled design.

2. Oncology Imaging and Theranostics Drive Molecular Imaging Adoption

Cancer care remains a major application area for molecular imaging because PET and other targeted imaging approaches can help clinicians characterize tumors, identify metastatic disease, evaluate recurrence, and assess therapeutic response. Japan is also moving toward theranostics, where molecular imaging is connected with targeted radionuclide treatment and personalized clinical decision-making. This trend is creating demand for improved PET systems, disease-specific tracers, and imaging agents targeting biological markers. The Japan Oncology Molecular Imaging Market is consequently supported by the expansion of precision oncology and radiopharmaceutical research.

In September 2025, GE HealthCare and Lantheus announced an exclusive Japanese licensing agreement for PYLARIFY, an F-18 imaging agent targeting PSMA-positive prostate-cancer lesions. Although PYLARIFY remained unapproved in Japan at the announcement, the agreement represented a significant development toward expanding PSMA-targeted PET imaging options in the country.

3. Hospital Modernization and Integrated Imaging Workflows Support Adoption

Japanese hospitals are increasingly looking for imaging technologies that combine diagnostic precision with operational efficiency. Molecular imaging equipment is evolving beyond standalone scanners toward integrated platforms incorporating automated workflows, AI-based reconstruction, quantitative tools, and connectivity with hospital information systems. These capabilities can reduce repetitive manual tasks, improve examination consistency, and support multidisciplinary clinical decision-making. The Japan Hospital Molecular Imaging Market is benefiting from investments in advanced imaging infrastructure at university hospitals, cancer centers, specialized diagnostic facilities, and regional medical institutions.

In Nov 2024, Siemens Healthineers continued expanding its PET/CT presence with the Biograph Trinion platform, which combines an air-cooled digital PET detector, low-dose CT technologies, and automated workflow capabilities. The platform was also subsequently adopted by Kinki University Hospital, demonstrating interest from Japanese hospitals in newer-generation PET/CT systems.

Critical Challenges Facing the Japan Molecular Imaging Industry

1. Radiopharmaceutical Supply and Infrastructure Complexity

Molecular imaging depends not only on sophisticated scanners but also on reliable access to radiopharmaceuticals, specialized production facilities, trained personnel, and carefully coordinated logistics. Many imaging agents have relatively short half-lives, making transportation, scheduling, storage, and administration more complicated than conventional diagnostic products. Hospitals may therefore need access to cyclotrons, radiopharmacy capabilities, specialized handling facilities, and appropriately trained staff. Expansion of advanced tracers can also require regulatory evaluation and clinical validation before broader adoption. These requirements can make molecular imaging infrastructure-intensive, particularly for smaller or regional hospitals. Japan’s industry is responding through greater development of radiopharmaceutical manufacturing, diagnostic-agent partnerships, and integrated supply arrangements, but maintaining dependable availability across different regions remains an important operational consideration for market expansion. GE HealthCare’s integration of Nippon Medphys into its organization illustrates the strategic importance of strengthening Japan’s radiopharmaceutical capabilities.

2. High Equipment Costs and Specialized Workforce Requirements

Advanced molecular imaging systems require substantial investment in equipment, facility preparation, maintenance, radiation-safety infrastructure, and specialized personnel. PET/CT and SPECT/CT systems also require experienced technologists and physicians capable of managing complex acquisition protocols, quantitative analysis, radiopharmaceutical procedures, and interpretation. Workforce shortages can therefore create operational pressure even when hospitals possess modern equipment. Japan’s healthcare institutions are increasingly seeking automated systems and AI-supported workflows to reduce repetitive tasks and improve consistency, but technology cannot completely replace specialist expertise. Training and continuing education remain essential as imaging platforms become more sophisticated. The introduction of new PET/CT technologies illustrates this challenge: manufacturers increasingly emphasize automated quality control, image reconstruction, workflow assistance, and simplified operation to help healthcare facilities manage advanced molecular imaging services efficiently.

Tokyo – Japan’s Molecular Imaging Innovation Hub

Tokyo represents a highly advanced environment for molecular imaging, supported by major hospitals, universities, cancer centers, research organizations, pharmaceutical companies, and medical-device manufacturers. The metropolitan ecosystem encourages collaboration between clinical researchers and technology developers, accelerating adoption of PET, SPECT, PET/CT, and emerging theranostic approaches. Oncology, neurology, and precision medicine are important application areas, while research institutions contribute to the development of new tracers and imaging methodologies. Tokyo also benefits from access to specialized radiopharmaceutical infrastructure and highly trained nuclear-medicine professionals. The concentration of clinical and research expertise encourages hospitals to evaluate advanced digital scanners, AI-assisted reconstruction, quantitative imaging, and targeted molecular diagnostics. This combination of healthcare sophistication and innovation makes Tokyo an important testing ground for next-generation molecular imaging technologies entering the Japanese clinical environment.

Kansai – A Powerful Center for Clinical Imaging and Research

The Kansai region provides a strong foundation for molecular imaging through its concentration of universities, advanced hospitals, pharmaceutical research, and medical-technology institutions. Osaka, Kyoto, and surrounding areas support extensive clinical research involving oncology, neurology, cardiovascular medicine, and nuclear medicine. Hospitals are increasingly interested in PET/CT technologies capable of delivering high-quality images while improving workflow efficiency and patient throughput. The region’s research environment also supports collaboration between academic institutions and medical-device companies, encouraging evaluation of advanced imaging systems and radiopharmaceutical applications. Kansai is particularly relevant to the development of theranostics and precision oncology because of its combination of clinical expertise and research infrastructure. The region can therefore contribute to broader adoption of molecular imaging by connecting technological innovation with practical hospital applications.

Aichi – Precision Imaging Meets Manufacturing Excellence

Aichi’s molecular imaging market benefits from its strong healthcare infrastructure and broader industrial ecosystem. Nagoya and surrounding areas host major hospitals, universities, research institutions, and technology-oriented organizations capable of supporting sophisticated diagnostic services. The region’s industrial expertise also creates opportunities for collaboration around medical equipment, digital technologies, automation, and healthcare engineering. Molecular imaging applications in oncology, cardiology, and neurological diagnosis can benefit from this environment as hospitals seek more accurate and efficient diagnostic workflows. Advanced PET/CT and SPECT systems, AI-supported interpretation, and quantitative imaging can help institutions improve clinical consistency while managing operational demands. Aichi’s location within Japan’s major economic and transportation network additionally supports access to specialized healthcare services and facilitates cooperation among manufacturers, research organizations, and medical institutions.

Kanagawa – Advanced Healthcare at the Tokyo Gateway

Kanagawa benefits from proximity to Tokyo while maintaining a substantial network of hospitals, research institutions, universities, and specialized healthcare organizations. Yokohama and neighboring areas provide an attractive environment for advanced imaging adoption, particularly in oncology, neurological diagnostics, and precision medicine. The region can leverage Tokyo’s broader research ecosystem while supporting its own clinical and technological capabilities. Molecular imaging facilities are increasingly incorporating PET/CT, PET/MRI, SPECT, AI-assisted image analysis, and quantitative imaging into specialized diagnostic pathways. Kanagawa also benefits from medical innovation activities involving universities, healthcare providers, and technology companies. Continued development of targeted radiopharmaceuticals and theranostic approaches could further strengthen demand for molecular imaging as hospitals seek tools capable of connecting disease visualization with personalized treatment planning.

Japan Single Photon Emission Computed Tomography Market

Japan’s Single Photon Emission Computed Tomography market is supported by the continuing importance of functional imaging in cardiovascular, neurological, oncological, and other specialized diagnostic applications. SPECT provides information about physiological activity that complements structural imaging modalities, making it valuable for evaluating blood flow, organ function, and disease-related changes. Japanese healthcare institutions are increasingly interested in semiconductor detector technologies, improved reconstruction, quantitative analysis, and workflow automation that can enhance image quality and examination efficiency. Integration with CT also strengthens anatomical localization and supports more comprehensive diagnostic assessment. The market is additionally influenced by Japan’s aging population, expanding demand for chronic-disease management, and advances in radiopharmaceutical development. Greater integration of SPECT with digital workflows and personalized medicine is expected to create further opportunities across hospitals and specialized diagnostic centers.

Japan Oncology Molecular Imaging Market

Japan’s Oncology Molecular Imaging market is evolving alongside precision cancer diagnosis and personalized treatment strategies. PET and PET/CT enable clinicians to visualize metabolic activity, characterize suspicious lesions, assess disease spread, identify recurrence, and evaluate treatment response. The development of targeted radiopharmaceuticals is further expanding molecular imaging beyond conventional metabolic tracers toward biologically specific imaging approaches. PSMA-targeted imaging for prostate cancer represents one important area of development, while theranostics is encouraging closer integration between molecular diagnosis and radionuclide treatment. Japanese hospitals and research institutions are also exploring AI-assisted reconstruction, quantitative imaging, and advanced PET technologies to improve clinical confidence and workflow efficiency. Partnerships between pharmaceutical companies, imaging manufacturers, research organizations, and healthcare providers are supporting this evolution. These developments position molecular imaging as an increasingly important component of Japan’s precision oncology ecosystem.

Japan Hospital Molecular Imaging Market

Japan’s Hospital Molecular Imaging market is shaped by the modernization of diagnostic infrastructure and growing demand for precise, efficient clinical imaging. Hospitals are adopting advanced PET/CT, SPECT/CT, and related digital technologies to support cancer diagnosis, neurological assessment, cardiovascular imaging, and treatment monitoring. New-generation platforms increasingly combine high-performance detectors with automated workflows, AI-assisted reconstruction, quantitative analysis, and compact designs. These capabilities can help hospitals manage complex examinations while improving consistency and supporting radiology and nuclear-medicine specialists. Large university hospitals and specialized cancer centers are important users because they combine clinical services with research and advanced treatment programs. At the same time, regional hospitals are increasingly evaluating technologies that offer easier installation and streamlined operation. The continued development of theranostics and targeted radiopharmaceuticals should further encourage hospital investment in molecular imaging infrastructure.

Market Segmentations

Modality

• Single Photon Emission Computed Tomography
• Psitron Emmission Tomography
• Nuclear Magnetic Resonance Spectrometer
• Molecular Ultrasound Imaging
• Others

Application

• Oncology
• Cardiovascular
• Neurology
• Respiratory
• Gastrointestinal

End Uses

• Hospitals
• Diagnostic Imaging Centers
• Research Institutes

Top 10 Cities

• Tokyo
• Kansai
• Aichi
• Kanagawa
• Saitama
• Hyogo
• Chiba
• Hokkaido
• Fukuoka
• Shizuoka

All Key Players have been covered with 5 Viewpoints

• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis

Key Players Analysis

1. GE HealthCare
2. Siemens Healthineers AG
3. Koninklijke Philips N.V.
4. Shimadzu Corp
5. United Imaging Healthcare Co., Ltd.
6. Bruker Corp
7. FUJIFILM Holdings Corp
8. Cubresa Inc.

Report Details: